Skip to main content Accessibility help
×
×
Home

The treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience

  • N. R. HUSSEIN (a1), I. TUNJEL (a2), Z. BASHARAT (a3), A. TAHA (a4) and W. IRVING (a5)...
Summary

Various variables that might influence the rapid and sustained virological response to recombinant PEG-IFN-α-2a were explored in Iraqi HCV-infected patients with haemoglobinopathy. Forty-three patients were evaluated for the relationship between rapid virological response (RVR), IL-28B polymorphism, viral load, liver enzyme levels, blood group, ultrasound findings, or HCV genotype and the sustained virological response (SVR) achievement. The overall RVR was 55·81% while the overall SVR was 53·49%. SVR in patients that achieved RVR was 82·61% (P = 0·0004). A significant association was found between initial alanine transaminase levels and viral load with SVR achievement (P = 0·025) and (P = 0·004), respectively. Thirty-two (74%) out of 43 of our samples were host genotyped at the IL-28B locus as CC, a significant association was found between CC group and SVR achievement (P = 0·04). Of our samples, 23/43 (53%) were typed as HCV genotype 4, 10/43 (23%) as genotype 1, 9/43 (20·9%) as genotype 3 and 1/43 (2·3%) as genotype 2. A significant association was found between genotype 3 and SVR achievement (P = 0·006). Multivariate analysis showed that only RVR achievement independently associated with SVR in the Iraqi population (P = 0·00). These results can be used to classify the patients requiring the more expensive new direct-acting antiviral drugs.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      The treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      The treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      The treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience
      Available formats
      ×
Copyright
Corresponding author
*Author for correspondence: Dr N. R. Hussein, Department of Internal Medicine, School of Medicine, Faculty of Medical Sciences, University of Duhok, Kurdistan Region, Iraq. (Email: nawfal.hussein@yahoo.com)
References
Hide All
1. Messina, JP, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2014; 61: 7787.
2. Antonov, K, et al. Predictors of sustained virological response (SVR) to pegylated interferon alpha (PEG-INF-a) and ribavirin (RBV) in patients with chronic hepatitis C infected with genotype 1. Journal of IMAB 2011; 17: 197199.
3. Hoofnagle, JH, Seeff, LB. Peginterferon and ribavirin for chronic hepatitis C. New England Journal of Medicine 2006; 355: 24442451.
4. Parruti, G, et al. Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48 h after the start of treatment with pegylated interferon and ribavirin. Antiviral Research 2010; 88: 124127.
5. Mirmomen, S, Alavian, SM. Treatment of HCV infection in multitransfused thalassemic patients: does liver iron status affect the outcome of response. Hepatitis Monthly 2005; 5: 1113.
6. Samuel, CE. Antiviral actions of interferons. Clinical Microbiology Reviews 2001; 14: 778809.
7. Lin, RJ, et al. Blocking of the alpha interferon-induced Jak-Stat signaling pathway by Japanese encephalitis virus infection. Journal of Virology 2004; 78: 92859294.
8. Poordad, F, Reddy, KR, Martin, P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clinical Infectious Diseases 2008; 46: 7884.
9. Martin-Carbonero, L, et al. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. Aids 2008; 22: 1521.
10. Legrand-Abravanel, F, et al. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. Journal of Medical Virology 2009; 81: 20292035.
11. Kamal, SM, et al. Peginterferon α-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54: 858866.
12. Huang, CF, et al. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. Journal of Hepatology 2012; 56: 3440.
13. Tanaka, Y, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nature Genetics 2009; 41: 11051109.
14. Ge, D, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399401.
15. Ferreira, CS, et al. A fast and cost-effective method for identifying a polymorphism of interleukin 28B related to hepatitis C. PLoS ONE 2013; 8: e78142.
16. Di Marco, V, et al. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood 2010; 116: 28752883.
17. Tabatabaei, SV, et al. Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy. Hepatitis Monthly 2012; 12: 372.
18. Al-Kubaisy, WA, Habib, KTA. Seroprevalence of hepatitis C virus specific antibodies among Iraqi children with thalassaemia. Eastern Mediterranean Health Journal 2006; 12: 204210.
19. Samimi-Rad, K, et al. Molecular epidemiology of hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. Journal of Medical Virology 2004; 74: 246252.
20. Koshy, A, et al. Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone. Journal of Clinical Gastroenterology 2002; 35: 8285.
21. Ohno, T, et al. Usefulness and limitation of phylogenetic analysis for hepatitis C virus core region: application to isolates from Egyptian and Yemeni patients. Archives of Virology 1996; 141: 11011113.
22. Suppiah, V, et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nature Genetics 2009; 41: 11001104.
23. Urban, TJ, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 18881896.
24. Rivero-Juarez, A, et al. HCV viral decline at week 2 of peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients. PLoS ONE 2014; 9: e99468.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed